Value
5.8/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 6.9 |
| P/S | 2.3 |
| Fwd P/E | 6.8 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 18.7x
- ▸PEG: 0.06
TGTX · Why this verdict
Why TG Therapeutics (TGTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.1/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
TG Therapeutics has built an elite business quality profile with 113% return on equity, 66% gross margins, and 70% revenue growth, but a complete 4-of-4 quarter earnings miss streak averaging -39.9% below consensus and 27% short interest create a fundamental tension between the operational quality of BRIUMVI and the company's ability to convert revenue into reported earnings.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Despite the earnings miss streak, TG Therapeutics achieves an elite 113% return on equity, 66% gross margins, a Rule of 40 score of 65, and 70% revenue growth — placing it in the top decile of its biotechnology peer group on both quality and growth dimensions simultaneously. Quality | Gross margins sustaining above 60% and revenue growth remaining above 40% year-over-year in the next 2 reported quarters would confirm the business model quality is intact even as the earnings misses create near-term noise. | →Stable |
| CounterA -7% free cash flow conversion to net income despite the high gross margins indicates the business is consuming cash through investments in commercial activities, and the ROE of 113% may partly reflect a low equity base rather than genuine capital efficiency. | ||
With revenue and business value concentrated in the BRIUMVI franchise and sole-source manufacturing relationships for active pharmaceutical ingredients, TG Therapeutics is highly exposed to any commercial setback, competitor launch, or supply chain disruption affecting that single product. Bear case | A second approved product generating meaningful revenue — defined as more than 10% of total quarterly revenue — within 12 months would begin to reduce the BRIUMVI single-asset dependency. | →Stable |
| CounterBRIUMVI for multiple sclerosis is a large and growing market, and a single strong-performing product with 70% revenue growth and 66% gross margins can sustain a high-quality business for years before the need for diversification becomes critical. | ||
TG Therapeutics missed earnings estimates in all 4 of the last 4 reported quarters by an average of -39.9% — including individual misses of -35.1%, -57.5%, -26.3%, and -40.9% — indicating that the revenue growth story is not translating into reported earnings at the rate the analyst community expected. Earnings | A positive earnings surprise in at least 1 of the next 2 reported quarters would represent the first break in the miss streak and signal that the gap between revenue and earnings is beginning to close. | →Stable |
| CounterGrowing biotech companies routinely invest heavily in commercial infrastructure and R&D during product launch phases, meaning earnings misses during a high-growth period can reflect intentional investment decisions rather than operational failures. | ||
With 27% of the float sold short — one of the highest short interest levels in the biotechnology sector — and a quality score of 7.5 that describes a strong underlying business, there is a structural tension that could resolve either through the shorts being proven right as earnings miss further or through a violent short squeeze if sentiment improves. Risk | Short interest declining below 15% of float within 90 days, representing a reduction of more than 40% from current levels, would signal that institutional short sellers are abandoning the bearish thesis. | →Stable |
| CounterHigh short interest in a biotech with a perfect earnings miss streak may reflect sophisticated investors with insight into the financial model — the consensus among these shorts may be that current revenue growth cannot sustainably convert to earnings at the valuation the market implies. | ||
Despite the earnings miss streak, TG Therapeutics achieves an elite 113% return on equity, 66% gross margins, a Rule of 40 score of 65, and 70% revenue growth — placing it in the top decile of its biotechnology peer group on both quality and growth dimensions simultaneously.
→StableQuality
- Expectation
- Gross margins sustaining above 60% and revenue growth remaining above 40% year-over-year in the next 2 reported quarters would confirm the business model quality is intact even as the earnings misses create near-term noise.
CounterA -7% free cash flow conversion to net income despite the high gross margins indicates the business is consuming cash through investments in commercial activities, and the ROE of 113% may partly reflect a low equity base rather than genuine capital efficiency.
With revenue and business value concentrated in the BRIUMVI franchise and sole-source manufacturing relationships for active pharmaceutical ingredients, TG Therapeutics is highly exposed to any commercial setback, competitor launch, or supply chain disruption affecting that single product.
→StableBear case
- Expectation
- A second approved product generating meaningful revenue — defined as more than 10% of total quarterly revenue — within 12 months would begin to reduce the BRIUMVI single-asset dependency.
CounterBRIUMVI for multiple sclerosis is a large and growing market, and a single strong-performing product with 70% revenue growth and 66% gross margins can sustain a high-quality business for years before the need for diversification becomes critical.
TG Therapeutics missed earnings estimates in all 4 of the last 4 reported quarters by an average of -39.9% — including individual misses of -35.1%, -57.5%, -26.3%, and -40.9% — indicating that the revenue growth story is not translating into reported earnings at the rate the analyst community expected.
→StableEarnings
- Expectation
- A positive earnings surprise in at least 1 of the next 2 reported quarters would represent the first break in the miss streak and signal that the gap between revenue and earnings is beginning to close.
CounterGrowing biotech companies routinely invest heavily in commercial infrastructure and R&D during product launch phases, meaning earnings misses during a high-growth period can reflect intentional investment decisions rather than operational failures.
With 27% of the float sold short — one of the highest short interest levels in the biotechnology sector — and a quality score of 7.5 that describes a strong underlying business, there is a structural tension that could resolve either through the shorts being proven right as earnings miss further or through a violent short squeeze if sentiment improves.
→StableRisk
- Expectation
- Short interest declining below 15% of float within 90 days, representing a reduction of more than 40% from current levels, would signal that institutional short sellers are abandoning the bearish thesis.
CounterHigh short interest in a biotech with a perfect earnings miss streak may reflect sophisticated investors with insight into the financial model — the consensus among these shorts may be that current revenue growth cannot sustainably convert to earnings at the valuation the market implies.
Per-dimension breakdown
Quality
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 5.7 |
| Gross margin | 10.0 |
| Op margin | 6.8 |
| Net margin | 10.0 |
| Current ratio | 7.2 |
| FCF quality | 0.0 |
| Moat | 7.5 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Excellent ROE: 113%
- ▸Strong margins: 66%
- ▸Earnings quality RED FLAG: -7% FCF/NI
- ▸Wide economic moat
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 70% YoY
Momentum
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.4 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 93)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 6.7 |
| Price target | 4.1 |
- ▸Light analyst coverage (7.0) — signal dampened
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
5.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.3 |
| quality rank | 9.8 |
| growth rank | 7.6 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.7 |
| support resistance | 1.2 |
| 52w position | 9.1 |
Risk (lower is worse)
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 10.0 |
| days to cover | 0.0 |
| volatility | 0.3 |
| put call | 0.0 |
| implied vol | 3.2 |
| max pain risk | 3.0 |
| beta | 4.4 |
| debt equity | 4.4 |
- ▸Short squeeze setup: 27% short, quality 7.5
- ▸Elevated put/call: 4.34
- ▸High IV: 61%
- ▸Above max pain $32
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 0B/4M
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more. | News modifier -2 (HOLD_IF_HOLDING → SELL_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD|L3:NEWS_MOD=-2Passed (7)
- MOMENTUM:4.7>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:39d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.2=NEGATIVE
Warning (1)
- MOMENTUM:4.7<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
-1.21
Upside
-18.1%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.68>1.3
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:4.7>=4.5. Top dim: Growth at 10.0; weakest: Catalyst at 3.0. No conviction either direction.
The strongest dimensions are Growth at 10.0, Quality at 7.3, and Sentiment at 5.9; the weakest are Catalyst at 3.0, Risk (lower is worse) at 3.2, and Technical at 4.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -1.21 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1With revenue and business value concentrated in the BRIUMVI franchise and sole-source manufacturing relationships for active pharmaceutical ingredients, TG Therapeutics is highly exposed to any commercial setback, competitor launch, or supply chain disruption affecting that single product.
Trip ifBRIUMVI revenue falls below 85% of total quarterly revenue, indicating either a new product is launching or BRIUMVI market share is being eroded by a competitor.
- P2TG Therapeutics missed earnings estimates in all 4 of the last 4 reported quarters by an average of -39.9% — including individual misses of -35.1%, -57.5%, -26.3%, and -40.9% — indicating that the revenue growth story is not translating into reported earnings at the rate the analyst community expected.
Trip ifEPS surprise falls below -50% in any reported quarter, indicating the earnings miss magnitude is accelerating beyond the current -40% average.
- P3Despite the earnings miss streak, TG Therapeutics achieves an elite 113% return on equity, 66% gross margins, a Rule of 40 score of 65, and 70% revenue growth — placing it in the top decile of its biotechnology peer group on both quality and growth dimensions simultaneously.
Trip ifGross margin falls below 55% in any reported quarter, indicating the high-margin product revenue mix is deteriorating or pricing pressure is increasing.
- P4With 27% of the float sold short — one of the highest short interest levels in the biotechnology sector — and a quality score of 7.5 that describes a strong underlying business, there is a structural tension that could resolve either through the shorts being proven right as earnings miss further or through a violent short squeeze if sentiment improves.
Trip ifShort interest rises above 35% of float, indicating that institutional short sellers are increasing their conviction in the bearish thesis rather than covering.